FDANews

Gilead Sciences to Invest 60 Million Euros in New Irish Facility

Gilead Sciences is planning to invest 60 million euros in developing a new world-class pharmaceutical plant in Dublin, Ireland, the country's Minister for Enterprise, Trade and Employment Micheál Martin announced.

The company is relocating its current Irish facilities, which have reached maximum capacity and are no longer able to meet manufacturing requirements, the minister said.

The new facility will include administrative offices, laboratories, a fill and finish facility and logistical and warehousing support structures. Gilead will also take into account future expansion requirements including a tableting facility and a financial shared services center.

"Gilead has been extremely pleased with operations in Ireland, based on a strong skills base and pro-business environment," Julie O'Neill, Gilead's general manager in Ireland, said. The company plans to complete construction of the new facility by late next year.

Gilead is a biopharmaceutical company that discovers, develops and commercializes treatments for HIV, hepatitis B and C and pulmonary arterial hypertension. The company's main activities in Ireland are the manufacture, packaging and distribution of products, including HIV medications for use in developing countries as part of the Gilead Access Program.